摘要
核苷(酸)类似物(NAs)是HBV复制的有效抑制剂,是目前大多数慢性乙型肝炎(CHB)患者抗病毒治疗的首选治疗方案。HBeAg血清学转换是评价HBeAg阳性CHB患者抗病毒治疗的持久性和有效性的重要指标。寻找能够预测NAs治疗CHB患者后发生HBeAg阴转/血清学转换的生物标志物,对于抗病毒治疗药物的选择、方案的调整、实现个体化治疗至关重要。综述了HBV DNA、HBV RNA、抗-HBc、HBcrAg等标志物对于预测NAs治疗CHB患者HBeAg转阴/血清学转换的价值。
Nucleos(t)ide analogues(NAs)are effective inhibitors for HBV replication and have become the preferred antiviral regimen for most patients with chronic hepatitis B(CHB).HBeAg seroconversion is an important index used to evaluate the durability and efficacy of antiviral therapy in HBeAg-positive CHB patients.The search for biomarkers that can predict HBeAg clearance or seroconversion after NAs treatment plays an important role in the selection of antiviral drugs,the adjustment of treatment regimens,and the achievement of individualized treatment.This article reviews the value of related markers,including HBV DNA,HBV RNA,anti-HBc,and HBcrAg,in predicting HBeAg clearance or seroconversion in CHB patients treated with NAs.
作者
蒋莹莹
郑素军
JIANG Yingying;ZHENG Sujun(Department of Severe Liver Disease,Beijing YouAn Hospital,Capital Medical University,Beijing 100069,China;Difficult&Complicated Liver Diseases and Artificial Liver Center,Beijing YouAn Hospital,Capital Medical University,Beijing 100069,China;Beijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research,Beijing YouAn Hospital,Capital Medical University,Beijing 100069,China)
出处
《临床肝胆病杂志》
CAS
北大核心
2020年第6期1358-1361,共4页
Journal of Clinical Hepatology
基金
国家十三五重大科技专项(2017ZX10202203-006)
国家十三五重大科技专项(2017ZX10302201-004)。
